Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

ExpreS2ion Biotechnologies – Presentation of Q3 2023 results

By HC Andersen Capital
ExpreS2ion Biotech Holding

This morning, Expres2ion Biotechnology released its Q3 2023 results. In a virtual live event today with CEO Bent Frandsen and CFO Keith Alexander we went through the results and achievements of the quarter. The management gave an update on the pipeline and lastly a status on the new strategy, focusing more on projects with shorter time to development and less risk.

ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines through the use of its non-viral Drosophila S2 cells-based expression system.

Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis 14.45, 16 November 2023.

Recent videos

Investor Day | Nov. 24, 2025
23.12.2025, 11.00 United Bankers
HCA Morgenbørs 23/12 - Flade futures og fokus på Novo Nordisk og Ørsted
23.12.2025, 09.27 Novo Nordisk
HCA Morgenbørs 22/12 - Positiv stemning i Asien og amerikanske futures i plus, mens Europa er fladt
22.12.2025, 09.28 GomSpace Group
HCA Morgenbørs 19/12 - Små fald i den europæiske åbning og fokus på flere danske aktier
19.12.2025, 09.25 Aquaporin
Talenom - Planned demerger and strategies of Talenom and Easor
18.12.2025, 11.00 Talenom
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.